长期护理机构已接种SARS-CoV-2疫苗老年人的谵妄发生率与预测因素
基于意大利60家长期护理机构的前瞻性队列研究,分析2521名≥60岁已接种疫苗居民,首次、第二剂和加强剂后谵妄发生率分别为3.5%、1.6%和1.5%;年龄、认知障碍、衰弱及既往抗精神病药或抗抑郁药使用是显著预测因素,厌食与谵妄强关联。
要点
- 接种后谵妄不常见,且随剂次增加发生率下降。
- 年龄、认知障碍、衰弱及精神药物使用可预测谵妄风险。
- 及时评估衰弱与认知障碍有助于分层谵妄风险并加强监测。
核心结论
- 接种SARS-CoV-2疫苗后谵妄不常见,且随剂次增加而下降。
- 及时评估衰弱和认知障碍可帮助分层长期护理机构居民的谵妄风险,便于加强预防和密切监测谵妄指标。
研究设计与样本
- 前瞻性队列研究,数据来自GeroCovid Vax多中心队列研究,由意大利老年学与老年医学学会和意大利国家卫生研究院联合开展,意大利药品管理局赞助。
- 纳入60家意大利长期护理机构中≥60岁且至少接种1剂抗SARS-CoV-2疫苗的居民,共分析2521人(平均年龄83.10±9.21岁,女性占70.7%)。
- 基线收集社会人口学、慢性病、用药、营养状态、认知与功能评估、移动能力和衰弱;接种第一剂、第二剂和加强剂后采用DSM-5标准评估谵妄;分析采用描述性统计、多因素logistic回归和网络分析。
主要发现
- 接种第一剂、第二剂和加强剂后谵妄发生率分别为3.5%、1.6%和1.5%。
- 年龄(OR 1.70,95%CI 1.08-2.77)、既往认知障碍(OR 2.05,95%CI 1.40-2.97)和衰弱(OR 1.77,95%CI 1.25-2.52)是谵妄的显著预测因素。
- 既往使用抗精神病药(OR 1.75,95%CI 1.22-2.51)和抗抑郁药(OR 1.77,95%CI 1.25-2.52)与谵妄显著相关。
- 网络分析显示厌食与谵妄之间存在强关联。
关键数值与推荐
- 谵妄评估采用DSM-5标准,在接种第一剂、第二剂和加强剂后进行。
- 谵妄发生率:第一剂后3.5%,第二剂后1.6%,加强剂后1.5%。
- 预测因素OR值:年龄1.70(95%CI 1.08-2.77),既往认知障碍2.05(95%CI 1.40-2.97),衰弱1.77(95%CI 1.25-2.52),既往抗精神病药1.75(95%CI 1.22-2.51),既往抗抑郁药1.77(95%CI 1.25-2.52)。
临床怎么用
- 对长期护理机构居民接种疫苗后,可结合年龄、认知障碍、衰弱及精神药物使用史进行谵妄风险分层。
- 对高风险居民加强预防措施并密切监测谵妄指标,同时关注厌食等关联症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: SARS-CoV-2 vaccination can bring an important benefit for older people in terms of reduction of mortality and hospitalization; however, reports of rare adverse effects like altered consciousness and delirium among this demographic have raised concerns. This study aimed to assess delirium incidence post-SARS-CoV-2 vaccination and its predictors in older residents across 60 Italian long-term care facilities (LTCFs). DESIGN: This is a prospective cohort study considering data from GeroCovid Vax, a multicenter cohort study jointly performed by the Italian Society of Gerontology and Geriatrics (SIGG) (Florence, Italy) and the Italian National Institute of Health (Istituto Superiore di Sanità-ISS, Rome, Italy), and sponsored by the Italian Medicines Agency (Agenzia Italiana del Farmaco-AIFA). SETTING AND PARTICIPANTS: GeroCovid Vax enrolled LTCFs residents aged ≥60 who received at least 1 anti-SARS-CoV-2 vaccine dose. METHODS: Baseline data covered sociodemographic details, chronic diseases, medications, nutritional status, cognitive and functional assessments, mobility, and frailty. Delirium was assessed post-first, second, and booster vaccine doses using DSM-5 criteria. Data analysis involved descriptive statistics, multivariate logistic regression, and network analysis. RESULTS: A total of 2521 participants (mean age 83.10 ± 9.21 years, 70.7% female) were analyzed. Delirium incidence post-first, second, and booster doses was 3.5%, 1.6%, and 1.5%, respectively. Age, preexisting cognitive disorders, and frailty were significant predictors of delirium, with odds ratios (ORs) of 1.70 (95% CI, 1.08-2.77), 2.05 (95% CI, 1.40-2.97), and 1.77 (95% CI, 1.25-2.52), respectively. Prior use of antipsychotics (OR, 1.75; 95% CI, 1.22-2.51) and antidepressants (OR, 1.77; 95% CI, 1.25-2.52) correlated significantly with delirium. Network analysis indicated a strong association between anorexia and delirium. CONCLUSION AND IMPLICATIONS: Post-vaccination delirium is infrequent and decreases with subsequent doses. Timely assessments for frailty and cognitive impairment could aid in stratifying delirium risk among LTCF residents, facilitating enhanced prevention measures and close monitoring for delirium indicators.
引用
- Okoye C, Zazzara MB, Ceolin C, et al. Delirium Incidence and Predictors in SARS-CoV-2 Vaccinated Residents in Long-Term Care Facilities (LTCF): Insights from the GeroCovid Vax Study. J Am Med Dir Assoc. 2024. PMID: 39245233. doi:10.1016/j.jamda.2024.105251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。